### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 21, 2020

#### **DLH Holdings Corp.**

(Exact Name of Registrant as Specified in Charter)

<u>New Jersey</u> (State or Other Jurisdiction of Incorporation)

0-18492 (Commission File Number)

22-1899798 (I.R.S. Employer Identification No.)

3565 Piedmont Road, NE Building 3, Suite 700 Atlanta, GA 30305 (Address of Principal Executive Offices, and Zip Code)

(866) 952-1647 strant's Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	DLHC	Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

Regi

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

{N0276857 }

#### Item 7.01 Regulation FD Disclosure.

Effective July 21, 2020, DLH Holdings Corp. ("DLH" or the "Company") has made available on the investor relations page of its corporate website the presentation materials attached hereto as Exhibit 99.1, which the Company will discuss during its participation in the Noble Capital Markets' Virtual Road Show Series on July 22, 2020 at 9:00, eastern time. A copy of the presentation materials will also be available under the "Presentations" tab on the investor relations page of DLH's website at https://dlhcorp.investorroom.com.

The information contained in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 7.01 and Exhibit 99.1 shall only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933 only if and to the extent such subsequent filing specifically references the information incorporated by reference herein.

#### Forward-Looking Statements

All statements in this Current Report on Form 8-K, and Exhibit 99.1 to this Current Report, that do not directly and exclusively relate to historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors many of which are outside DLH's control. You can identify forward-looking statements by words such as "expects," "intends," "plans," "believes," "anticipates," and similar words or phrases. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH's actual results to differ materially from those indicated by the forward-looking statements. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus ("COVID-19"), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties, which and other covenants; changes of managing larger and more widespread operations; contract awards in connection with re-competes for present business and/or competition for new business; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations of future acquisitions; and other risks desc

(d) Exhibits

The following exhibit is attached to this Current Report on Form 8-K:

Exhibit Number	Exhibit Title or Description

<u>99.1</u> <u>Presentation Materials\*</u> \* Furnished herewith.

{N0276857} 1

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

### DLH Holdings Corp.

By: /s/ Kathryn M. JohnBull

Name: Kathryn M. JohnBull Title: Chief Financial Officer

Date: July 21, 2020

{N0276857} 2



### **Investor Presentation**

ZACH PARKER | PRESIDENT & CEO KATHRYN JOHNBULL | CFO JULY 21, 2020

### Forward-looking Statements

### "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. T statements relate to future events or DLH's future financial performance. Any statements that refer to expectations, projections or c characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to effect that the Company or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be consid forward looking statements that involve risks and uncertainties which could cause actual events or DLH's actual results to differ materially those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regar estimates of future revenues, operating income, earnings, earnings per share, backlog, and cash flows. These statements reflect our belief assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statem made in this release due to a variety of factors, including: the outbreak of the novel coronavirus ("COVID-19"), including the measures to reits spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacer other risks and uncertainties; the risk that we will not realize the anticipated benefits of an acquisition; the challenges of managing larger more widespread operations resulting from the acquisition; contract awards in connection with re-competes for present business an competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; governi contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termini risks; the ability to successfully integrate the operations of future acquisitions; and other risks described in our SEC filings. For a discussic such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Fac in the Company's periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2 as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are base current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statem as\_may be required by law.



# Agenda




OVERVIEW



FINANCIAL HIGHLIGHTS



QUESTIONS AND ANSWERS




Zach Parker President & CEO DLH Holdings Corp.




Kathryn M. JohnBull Chief Financial Officer, DLH Holdings Corp.


## 


# **DLH's Transformation Journey**



### **Business Overview**







## Unique Value Proposition

# **Organic Growth Drivers**



### Healthy Growth Profile





### COVID-19 Impact / Opportunities

Defense & Veterans Health Solutions



Human Services and Solutions



Public Health and Life Sciences



### DLH TACKLING COVID-19 FOR THE VA, DOD, CDC, NIH, AND OTHERS

- Care and treatment of military
- · Rx expansion for veterans
- Prospects for behavioral health
- Specialized communications
- · Pandemic-related websites
- Social media outreach / metrics
- Clinical trials for therapeutics and vaccine development
- Preparedness & Response
- Environmental Implications



## New COVID-19 Public Health & Life Sciences Work




### CLINICAL RESEARCH TRIALS & LABORATORY SERVICES

- Over \$15 million of new awards thus far in calendar 2020
- Conducting trials of the safety and efficacy of investigational therapeutics for the treatment of COVID-19
- Observational studies of outpatients with COVID-19
- Clinical Research Organization support services to provide infrastructure to exchange data among scientific stakeholders
- · Large network consortium of partner medical centers, clinics, academic institutic
- · Study of immune aging in smokers in relation to COVID susceptibility
- Investigating interactions of COVID-19 with chronic diseases including types of cancer, heart disease, lung disease, and more

## **DLH Achieves FedRAMP Ready Status**

Opens Door to Federal Business Opportunities for Cloud-Based Platform-As-A-Service (PaaS)



# Financial Highlights

Kathryn JohnBull | CFO



**OLH** 


# A History of Growth...




### **Historical Revenue**

# And Expanding Value


### **Historical EBITDA**





Revenue

# Fiscal Q2 Results (Three Months Ended 3/31/2020)



**Operating Income** 

## Debt Paydown Strategy in Place

	6/7/2019	9/30/2019	3/31/2020
Debt Balance*	\$70 M	\$56 M	\$55 M
Less cash on hand	\$1.9	\$1.8	\$1.1
Net Debt	\$68.1 M	\$54.2 M	\$53.9 M**

\*\$70M originally, after acquisition of S3


\*\*3/31/20 balances reflect delays from financial system integration

Increased operating cash flow anticipated in subsequent quarters leading to a projected year-end debt balance of \$42 to \$45 million.

Net Debt is a non-GAAP metric used by investors and lenders and management believes it provides relevant and useful information to investors and other users of our financial data. Net Debt is calculated by subtracting cash and cash equivalents from the sum of current and long-term debt



### **Our Four Levers of Value Creation**





# **Q&A** Session

Zach Parker | President and CEO Kathryn JohnBull | CFO



**OLH** 

# Appendix

#### Non-GAAP Reconciliations:

This document contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. These measures should be used in conjunction with, rather than instead of, their comparable GAAP measures. A reconciliation of non-GAAP measures to the comparable GAAP measures presented in this document follows.

### **OLH**



# Fiscal 2020 Results (\$000s)

		Three Mo Mar	Six Months Ended March 31,						
	2020			2019		2020	2019		
Revenue	\$	54,798	\$	\$ 33,756		107,036	\$	67,508	
Cost of Operations:									
Contract costs		42,941		26,250		84,281		52,706	
General and administrative costs		6,260		4,477		12,174		8,653	
Acquisition costs		-		143				143	
Depreciation and amortization		1,760		560		3,619		1,123	
Total operating costs		50,961		31,430		100,074		62,625	
Income from operations		3,837		2,326		6,962	4,883		
Interest expense, net		906		544		1,846		721	
Income before income taxes		2,931		1,782		5,116		4,162	
Income tax expense		855		517		1,488		1,207	
Net income	\$	2,076	\$	1,265	\$	3,628	\$	2,955	
Net income per share - basic	S	0.17	\$	0.11	\$	0.30	\$	0.25	
Net income per share - diluted	\$	0.16	\$	0.10	\$	0.28	\$	0.23	
Weighted average common shares outstanding									
Basic		12,299		12,036		12,193		11,999	
Diluted		13,003		13,087		12,886		13,030	

## **Trending EBITDA Reconciliation**

	Twelve Months Ended															
							Septe	ember 30,								
Amounts in \$000s	2013		2014		2015		2016		2017		2018		2019		TTM*	
Net (loss)/income	\$	(159)	\$	5,357	\$	8,728	\$	3,384	\$	3,288	\$	1,836	\$	5,324	\$	5,995
(i) Interest expense/other (income)		407		4		(744)		823		1,228		1,116		2,473		3,599
(ii) (Benefit)/provision for taxes		5		(4,597)		(5,488)		(938)		2,114		5,830		2,171		2,453
(iii) Depreciation and amortization		121		106		55		1,244		1,754		2,242		3,956		6,452
EBITDA	\$	369	\$	870	\$	2,551	\$	4,513	\$	8,384	\$	11,024	\$	13,924	\$	18,499

\*TTM is the trailing twelve months ending March 31, 2020

### CORPORATE HEADQUARTERS ATLANTA HQ

3565 Piedmont Road, NE Building 3 | Suite 700 Atlanta, GA 30305 NATIONAL CAPITAL REGION HQ

8757 Georgia Avenue Suite 1200 Silver Spring, MD 20910

### RESEARCH TRIANGLE DURHAM, NORTH CAROLINA OFFICES

4505 Emperor Boulevard Suite 400 Durham, NC 27703



Your Mission Is Our Passion